Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2022

Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

1 CIMA - Center for Applied Medical Research [Plamplona]
2 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
3 ISC - Instituto de Salud Carlos III [Madrid]
4 Yong Loo Lin School of Medicine [Singapore]
5 NUS - National University of Singapore
6 University of Otago [Dunedin, Nouvelle-Zélande]
7 UMCG - University Medical Center Groningen [Groningen]
8 MHH - Medizinische Hochschule Hannover = Hannover Medical School
9 Fraunhofer ITEM - Fraunhofer Institute for Toxicology and Experimental Medicine
10 Medizinische Universität Wien = Medical University of Vienna
11 DZHK - German Center for Cardiovascular Research
12 FMUP - Faculdade de Medicina da Universidade do Porto
13 Departments of Cardiology and Cardiac Surgery, and Nephrology, Clínica Universidad de Navarra
14 Clínica Universidad de Navarra [Pamplona]
15 SSSUP - Scuola Universitaria Superiore Sant'Anna [Pisa]
16 Fondazione Toscana Gabriele Monasterio
17 Montreal Heart Institute - Institut de Cardiologie de Montréal
18 Cairo University - Faculty of Medicine
19 OCSC - Onassis Cardiac Surgery Center [Athens]
20 Charité Campus Virchow-Klinikum (CVK)
21 BCRT - Berlin-Brandenburg Center for Regenerative Medicine [Berlin, Germany]
22 MSU - Université d'État Lomonossov de Moscou = Lomonosov Moscow State University
23 Cardiology Department, Rabin Medical Center
24 Hôpital Lariboisière-Fernand-Widal [APHP]
25 UKS - Saarland University Hospital
26 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
27 LUMC - Leiden University Medical Center
28 Wrocław Medical University
29 HNC - Hôpital national = Rigshospitalet [Copenhagen, Denmark]
30 QUB - Queen's University [Belfast]
31 LIU - Linköping University
32 Massachusetts General Hospital [Boston]
33 Baim Institute for Clinical Research Boston MA
34 BHF GCRC - British Heart Foundation Glasgow Cardiovascular Research Centre
35 VSMU - Volgograd State Medical University [Russian Federation]
36 Karolinska University Hospital [Stockholm]
37 Karolinska Institutet [Stockholm]
38 Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia]
39 UniBs - Università degli Studi di Brescia = University of Brescia
40 University of Zagreb
41 Cardiology Department, Porto Armed Forces Hospital
42 University Hospital Basel [Basel]
43 ZOL - Ziekenhuis Oost-Limburg
44 UV - Universitat de València
45 Hospital Clínico Universitario de Valencia
46 Cardiology Division, Castelsangiovanni Hospital
47 Scientific Research Institute of Cardiology and Internal Medicine [Almaty, Kazakhstan]
48 University Clinical Centre of Serbia
49 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
50 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
51 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
52 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
53 University of Naples Federico II = Università degli studi di Napoli Federico II
54 BIH - Berlin Institute of Health
55 IRCCS Ospedale San Raffaele [Milan, Italy]
56 SASA - Serbian Academy of Sciences and Arts
57 University of Belgrade [Belgrade]
58 St George’s University Hospitals
59 University of Warwick [Coventry]
60 GTPUH - Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain]
61 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona

Résumé

Cardiac remodelling refers to changes in left ventricular structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery (reverse remodelling) in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leucocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g. proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and several biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of this review paper on biomarkers of cardiac remodelling.
Fichier principal
Vignette du fichier
Cardiac remodeling part 1.pdf (1.84 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03800912 , version 1 (06-10-2022)

Identifiants

Citer

Arantxa González, A. Mark Richards, Rudolf A de Boer, Thomas Thum, Henrike Arfsten, et al.. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24 (6), pp.927-943. ⟨10.1002/ejhf.2493⟩. ⟨hal-03800912⟩
66 Consultations
52 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More